Funding for this research was provided by:
Wellcome Trust (209407/Z/17/Z)
British Heart Foundation (PG/12/54/29734, PG/17/1/32532, FS/SBSRF/20/31005, PG/17/58/33134)
Received: 20 September 2021
Accepted: 12 April 2022
First Online: 3 May 2022
: W.L. is a founder and scientific advisor to Morphogen-IX. N.W.M. is a founder and CEO of Morphogen-IX. Other authors declare no competing interest.